View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsApures 将来の成長Future 基準チェック /06現在、 Apuresの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 12Apures Co., Ltd., Annual General Meeting, Mar 31, 2026Apures Co., Ltd., Annual General Meeting, Mar 31, 2026, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South KoreaNew Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (₩5.64b market cap, or US$4.05m).New Risk • Apr 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₩7.68b market cap, or US$5.42m).お知らせ • Mar 08Apures Co., Ltd., Annual General Meeting, Mar 28, 2025Apures Co., Ltd., Annual General Meeting, Mar 28, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South KoreaNew Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (₩12.9b market cap, or US$9.61m).New Risk • Jul 04New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩18.0b market cap, or US$13.9m).お知らせ • Mar 19Apures Co., Ltd. announced that it has received KRW 2.999998485 billion in fundingOn March 17, 2021, Apures Co., Ltd. (XKON:A149300) closed the transaction.Is New 90 Day High Low • Mar 11New 90-day low: ₩2,510The company is down 26% from its price of ₩3,390 on 11 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.お知らせ • Mar 11Apures Co., Ltd. announced that it expects to receive KRW 2.999998485 billion in fundingApures Co., Ltd. (XKON:A149300) announced a private placement to issue 1,204,335 shares at a price of KRW 2,491 per share for gross proceeds of KRW 2,999,998,485 to new investor, Genen Bio on March 9, 2021 The face value is KRW 500 per share. The company is raising funding through third party allocation increase method. The transaction is expected to close by March 17, 2021. The transaction has approved by the board of directors of the company.Is New 90 Day High Low • Dec 07New 90-day high: ₩3,450The company is up 146% from its price of ₩1,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day high: ₩1,950The company is up 21% from its price of ₩1,610 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day high: ₩1,810The company is up 5.0% from its price of ₩1,730 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.お知らせ • Jul 18Apures Co., Ltd. announced that it has received KRW 2.889 billion in funding from AmWest Funding Corp.On July 14, 2020, Apures Co., Ltd. (XKON:A149300) closed the transaction.お知らせ • Jul 17Apures Co., Ltd. announced that it expects to receive KRW 2.889 billion in funding from AmWest Funding Corp. and another investorApures Co., Ltd. (XKON:A149300) announced a private placement to issue series 8 non-guaranteed private equity convertible bonds for proceeds of KRW 2,389,000,000 and series 9 registered title of interest-free bond for proceeds of KRW 500,000,000, for aggregate gross proceeds of KRW 2,889,000,000 on July 10, 2020. The transaction will include participation from AmWest Funding Corp. series 8 bonds and M. West Funding Korea for series 9 bonds. The series 8 carry fixed coupon rate of 4% per annum and series 9 bonds have a surface interest rate of 4% and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares, representing 3.98% of the company and series 9 bonds are fully convertible into 260,010 shares, representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period for both the bonds will start from July 14, 2021 and ends on July 13, 2023. The bonds carry fixed coupon rate of 4% per annum and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares and series 9 bonds are full convertible into 260,010 common shares representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period will start from July 14, 2021 and ends on July 13, 2023. The transaction is expected to close on July 14, 2020. The transaction has been approved by the board of directors of the company. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Apures は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XKON:A149300 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: A149300の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A149300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A149300の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A149300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A149300の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A149300の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 23:17終値2026/05/19 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Apures Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 12Apures Co., Ltd., Annual General Meeting, Mar 31, 2026Apures Co., Ltd., Annual General Meeting, Mar 31, 2026, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South Korea
New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (₩5.64b market cap, or US$4.05m).
New Risk • Apr 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₩7.68b market cap, or US$5.42m).
お知らせ • Mar 08Apures Co., Ltd., Annual General Meeting, Mar 28, 2025Apures Co., Ltd., Annual General Meeting, Mar 28, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South Korea
New Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (₩12.9b market cap, or US$9.61m).
New Risk • Jul 04New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩18.0b market cap, or US$13.9m).
お知らせ • Mar 19Apures Co., Ltd. announced that it has received KRW 2.999998485 billion in fundingOn March 17, 2021, Apures Co., Ltd. (XKON:A149300) closed the transaction.
Is New 90 Day High Low • Mar 11New 90-day low: ₩2,510The company is down 26% from its price of ₩3,390 on 11 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.
お知らせ • Mar 11Apures Co., Ltd. announced that it expects to receive KRW 2.999998485 billion in fundingApures Co., Ltd. (XKON:A149300) announced a private placement to issue 1,204,335 shares at a price of KRW 2,491 per share for gross proceeds of KRW 2,999,998,485 to new investor, Genen Bio on March 9, 2021 The face value is KRW 500 per share. The company is raising funding through third party allocation increase method. The transaction is expected to close by March 17, 2021. The transaction has approved by the board of directors of the company.
Is New 90 Day High Low • Dec 07New 90-day high: ₩3,450The company is up 146% from its price of ₩1,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day high: ₩1,950The company is up 21% from its price of ₩1,610 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day high: ₩1,810The company is up 5.0% from its price of ₩1,730 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.
お知らせ • Jul 18Apures Co., Ltd. announced that it has received KRW 2.889 billion in funding from AmWest Funding Corp.On July 14, 2020, Apures Co., Ltd. (XKON:A149300) closed the transaction.
お知らせ • Jul 17Apures Co., Ltd. announced that it expects to receive KRW 2.889 billion in funding from AmWest Funding Corp. and another investorApures Co., Ltd. (XKON:A149300) announced a private placement to issue series 8 non-guaranteed private equity convertible bonds for proceeds of KRW 2,389,000,000 and series 9 registered title of interest-free bond for proceeds of KRW 500,000,000, for aggregate gross proceeds of KRW 2,889,000,000 on July 10, 2020. The transaction will include participation from AmWest Funding Corp. series 8 bonds and M. West Funding Korea for series 9 bonds. The series 8 carry fixed coupon rate of 4% per annum and series 9 bonds have a surface interest rate of 4% and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares, representing 3.98% of the company and series 9 bonds are fully convertible into 260,010 shares, representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period for both the bonds will start from July 14, 2021 and ends on July 13, 2023. The bonds carry fixed coupon rate of 4% per annum and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares and series 9 bonds are full convertible into 260,010 common shares representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period will start from July 14, 2021 and ends on July 13, 2023. The transaction is expected to close on July 14, 2020. The transaction has been approved by the board of directors of the company.